Epirubicin
- PDF / 169,845 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 28 Downloads / 147 Views
1 S
Acute necrotic-haemorrhagic pancreatitis: case report A 69-year-old man developed acute necrotic-haemorrhagic pancreatitis following trans-arterial chemoembolisation (TACE) with epirubicin for hepatocellular carcinoma. The man, who had a history of hepatic cirrhosis and chronic alcohol consumption, was diagnosed with multicentric hepatocellular carcinoma. Therefore, he underwent TACE via the right trans-femoral approach, wherein the embolisation was performed using 100 microns microsphere beads loaded with epirubicin 100mg [route not stated]. Following the procedure, he received prophylactic antibacterial therapy with cefoperazone/sulbactam. However, within 24 hours of the TACE procedure, he developed significant abdominal pain, especially epigastric pain, which was associated with headache and vomiting. On the day following the TACE, WBC count was noted to be 15.4 t/cmm on complete blood count. Serum amylase and lipase were noted to be 1826 U/L and 2377 U/L respectively. Liver function tests revealed a moderate elevation of serum AST (262 IU/L) and ALT (82 IU/L). Also, moderately elevated serum total bilirubin was observed. Echografic re-evaluation demonstrated interhepatodiaphragmatic and perisplenic fluid, and a CT scan of the abdomen with contrast revealed acute necrotic-haemorrhagic pancreatitis, with a Balthazar score D. Subsequently, he was diagnosed with TACE with epirubicin-induced acute necrotic-haemorrhagic pancreatitis. Therefore, the treatment was immediately established [outcome not stated]. Ana-Maria C, et al. Acute necrotic-haemorrhagic pancreatitis as a rare complication of trans-arterial chemoembolization of hepatocellular carcinoma - Case report. Journal of 803497846 Gastrointestinal and Liver Diseases 28 (Suppl. 2): 82 abstr. PP 83, Jun 2019. Available from: URL: https://www.jgld.ro/jgld/index.php/jgld/supplements [abstract]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
